8-K: Varex Imaging Reports Solid Q1 2025 Results, Revenue Up 5%

Varex Imaging Corporation announces its first quarter fiscal year 2025 financial results, with revenue reaching $200 million, a 5% increase year-over-year, and improved profitability.

Summary

• Varex Imaging Corporation reported its unaudited financial results for the first quarter of fiscal year 2025.
• Revenue reached $200 million, a 5% increase compared to the same period last year.
• The Medical segment contributed $145 million in revenue, up 3% year-over-year, while the Industrial segment generated $55 million, a 10% increase.
• GAAP gross margin was 34%, and non-GAAP gross margin was 35%.
• GAAP operating margin was 6%, and non-GAAP operating margin was 7%.
• The company reported a GAAP net loss of $0.01 per diluted share but a non-GAAP net earnings of $0.07 per diluted share.
• Cash flow from operations was $10 million.
• The company's cash, cash equivalents, and marketable securities totaled $219 million at the end of the quarter.
• For the second quarter of fiscal year 2025, Varex expects revenues between $200 million and $215 million and non-GAAP net earnings per diluted share between $0.05 and $0.20.

Sentiment

Score: 7

Explanation: The sentiment is positive due to revenue growth, improved profitability, and a strong cash position. However, the GAAP net loss and the inherent risks in the industry temper the overall outlook.

Positives

• Revenue increased by 5% year-over-year.
• Both Medical and Industrial segments showed revenue growth.
• Non-GAAP gross margin improved significantly.
• Non-GAAP EPS increased.
• The company maintains a strong cash position.
• Management expects continued solid demand in both segments for the next quarter.

Negatives

• The company reported a GAAP net loss of $0.01 per diluted share for the quarter.

Risks

• The company acknowledges risks and uncertainties that could cause actual results to differ materially from forward-looking statements, including customer loss, competition, economic instability, supply chain disruptions, and intellectual property issues.
• The preliminary financial results are subject to change pending the filing of the Form 10-Q.

Future Outlook

Varex expects revenues between $200 million and $215 million and non-GAAP net earnings per diluted share between $0.05 and $0.20 for the second quarter of fiscal year 2025.

Management Comments

• Sunny Sanyal, Chief Executive Officer, stated, 'Demand in the first quarter was solid, with both Medical and Industrial revenue up year-over-year.'
• Sanyal added, 'Favorable sales mix and productivity gains across both segments resulted in higher than expected profitability and earnings per share.'
• Sanyal also mentioned, 'We expect to see continued solid demand across both segments in the second quarter of fiscal 2025.'

Industry Context

Varex Imaging operates in the X-ray imaging components and systems market, serving both medical and industrial applications. The company's performance reflects the demand trends in these sectors, with growth in both segments indicating a healthy market environment. Competitors in this space include companies specializing in medical imaging equipment and industrial inspection solutions.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without knowing the specific performance of Varex's direct competitors this quarter.
• However, a 5% revenue growth is generally a positive sign in the medical and industrial imaging sectors, which are often characterized by steady but not explosive growth.
• Companies like Canon Medical Systems, Siemens Healthineers, and GE Healthcare are major players in the medical imaging space, and their performance can provide a broader context.
• In the industrial sector, companies like Olympus and Nikon offer competing solutions.
• Varex's improved non-GAAP gross margin suggests effective cost management and pricing strategies compared to industry averages.

Stakeholder Impact

• Shareholders will likely react positively to the revenue growth and improved profitability.
• Employees may benefit from the company's positive performance and outlook.
• Customers can expect continued innovation and product development from Varex.
• Suppliers may see increased demand for their products and services.
• Creditors can be reassured by the company's strong financial position.

Next Steps

• Varex will conduct its earnings conference call on February 6, 2025, at 3:00 p.m. Mountain Time.
• The company will file its Form 10-Q for the first quarter of fiscal year 2025.

Key Dates